Status:
COMPLETED
Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Cystic Fibrosis Foundation
Windtree Therapeutics
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
14+ years
Phase:
PHASE2
Brief Summary
Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The i...
Detailed Description
This single-center pilot study is designed as a double-blind, randomized, cross-over clinical trial to evaluate the effects of inhaled lucinactant, an investigational peptide-containing synthetic surf...
Eligibility Criteria
Inclusion
- Cystic fibrosis
- FEV1\>40%
Exclusion
- Unstable lung disease
- Unable or unwilling to stop hypertonic saline and dornase alfa for 3 days prior to each study period
- Relevant drug allergy or intolerance
- Recent investigational drug use (30 days)
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00934362
Start Date
October 1 2008
End Date
August 1 2010
Last Update
March 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina
Chapel Hill, North Carolina, United States, 27599